Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Anadys, Structural GenomiX Form Antibacterials Alliance

Feb. 21, 2002

By Aaron Lorenzo

Cytyc Acquiring Digene In Stock, Cash Deal Worth $554M

Feb. 20, 2002

By Aaron Lorenzo

Cytyc Acquiring Digene In Stock, Cash Deal Worth $554M

Feb. 20, 2002

By Aaron Lorenzo

Norak Closes Series B, Raises $13M For Screening Platform

Feb. 7, 2002

By Aaron Lorenzo

Chiron Licenses TB Product To Public-Private Partnership

Feb. 4, 2002

By Aaron Lorenzo

Biogen, Genaissance Align In Pharmacogenomics Area

Feb. 4, 2002

By Aaron Lorenzo

Biogen, Genaissance Align In Pharmacogenomics Area

Feb. 4, 2002

By Aaron Lorenzo

Chiron Licenses TB Product To Public-Private Partnership

Feb. 4, 2002

By Aaron Lorenzo

Intradigm, DirectGene Team Up To Develop Cancer Therapeutics

Jan. 28, 2002

By Aaron Lorenzo

Intradigm, DirectGene Team Up To Develop Cancer Therapeutics

Jan. 28, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 12, 2025.
AACR 2025: Induced proximity strategy, beyond degraders
BioWorld
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
Navigating the Trump tariffs, part two: Amgen, Biogen, others
BioWorld
As biopharma companies continue to roll out their first-quarter earnings, Trump administration tariffs remain at the top of investors’ minds. While executives...
Little bite from voluntary most-favored nation Rx pricing order
BioWorld
After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...